Trial Profile
To assess whether administration of two doses of an oral, irreversible inhibitor of Brutons tyrosine kinase (BTK) (Ibrutinib) reduces allergic responses in food allergic subjects and eliminates IgE mediated basophil activation ex vivo
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Mar 2018
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Food hypersensitivity
- Focus Therapeutic Use
- 23 Mar 2018 New trial record
- 05 Mar 2018 Results presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology